Sanibel Captiva Trust Company Inc. Buys 4,065 Shares of Eli Lilly and Company (NYSE:LLY)

Sanibel Captiva Trust Company Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,165 shares of the company's stock after purchasing an additional 4,065 shares during the quarter. Sanibel Captiva Trust Company Inc.'s holdings in Eli Lilly and Company were worth $18,655,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Howard Financial Services LTD. increased its holdings in shares of Eli Lilly and Company by 47.0% during the fourth quarter. Howard Financial Services LTD. now owns 632 shares of the company's stock valued at $488,000 after acquiring an additional 202 shares in the last quarter. Integrated Investment Consultants LLC raised its holdings in Eli Lilly and Company by 0.3% in the 4th quarter. Integrated Investment Consultants LLC now owns 696,167 shares of the company's stock worth $537,441,000 after acquiring an additional 2,000 shares during the last quarter. Arkadios Wealth Advisors raised its stake in shares of Eli Lilly and Company by 3.2% in the fourth quarter. Arkadios Wealth Advisors now owns 6,748 shares of the company's stock worth $5,209,000 after purchasing an additional 207 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its position in shares of Eli Lilly and Company by 1.5% during the fourth quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 2,900 shares of the company's stock valued at $2,239,000 after buying an additional 42 shares during the last quarter. Finally, InTrack Investment Management Inc increased its holdings in Eli Lilly and Company by 28.8% in the 4th quarter. InTrack Investment Management Inc now owns 4,516 shares of the company's stock worth $3,364,000 after buying an additional 1,011 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 4.1 %

Shares of NYSE:LLY traded down $31.36 during trading on Monday, reaching $726.24. The company's stock had a trading volume of 5,497,108 shares, compared to its average volume of 2,736,766. The stock has a market capitalization of $689.43 billion, a PE ratio of 78.51, a price-to-earnings-growth ratio of 1.66 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $612.70 and a 12 month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm's 50 day simple moving average is $781.14 and its two-hundred day simple moving average is $854.04.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company's revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 13.14 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has approved a stock buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. Eli Lilly and Company's payout ratio is 56.22%.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on LLY shares. Wolfe Research initiated coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They set an "outperform" rating and a $1,000.00 price target on the stock. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, January 1st. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an "outperform" rating and a $1,100.00 price target on the stock. Citigroup raised their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Friday, October 25th. Finally, Bank of America reiterated a "buy" rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.